57381-26-7 | Irsogladine

Packsize	Purity	Availability	Price	Discounted Price
1mg	99%	in stock	$16.00	$11.00
25mg	99%	in stock	$20.00	$14.00
250mg	99%	in stock	$53.00	$37.00
1g	99%	in stock	$120.00	$84.00
5g	99%	in stock	$490.00	$343.00

Description

• Catalog Number: AI52862
• Chemical Name: Irsogladine
• CAS Number: 57381-26-7
• Molecular Formula: C9H7Cl2N5
• Molecular Weight: 256.0914
• MDL Number: MFCD00866871
• SMILES: Clc1ccc(c(c1)c1nc(N)nc(n1)N)Cl
• NSC Number: 759836

Computed Properties

• Complexity: 232
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 16
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 1
• XLogP3: 2

Literature

• The anti-ulcer agent, irsogladine, increases insulin secretion by MIN6 cells.

  European journal of pharmacology 20120615

• Irsogladine maleate ameliorates inflammation and fibrosis in mice with chronic colitis induced by dextran sulfate sodium.

  Medical molecular morphology 20120601

• Irsogladine maleate regulates epithelial barrier function in tumor necrosis factor-α-stimulated human gingival epithelial cells.

  Journal of periodontal research 20120201

• Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: a randomized, controlled, prospective study.

  Scandinavian journal of gastroenterology 20110301

• Irsogladine maleate regulates neutrophil migration and E-cadherin expression in gingival epithelium stimulated by Aggregatibacter actinomycetemcomitans.

  Biochemical pharmacology 20100515

• Clinical trial: irsogladine maleate, a mucosal protective drug, accelerates gastric ulcer healing after treatment for eradication of Helicobacter pylori infection--the results of a multicentre, double-blind, randomized clinical trial (IMPACT study).

  Alimentary pharmacology & therapeutics 20100401

• Irsogladine Maleate in the management of recurrent aphthous stomatitis: a pilot study.

  Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry 20100101

• Effect of irsogladine maleate on NSAID-induced reduction of gastric mucosal blood flow in anesthetized dogs.

  Digestion 20090101

• Prophylactic effect of irsogladine maleate against indomethacin-induced small intestinal lesions in rats.

  Digestive diseases and sciences 20081001

• Irsogladine maleate abolishes the increase in interleukin-8 levels caused by outer membrane protein 29 from Aggregatibacter (Actinobacillus) actinomycetemcomitans through the ERK pathway in human gingival epithelial cells.

  Journal of periodontal research 20081001

• Irsogladine maleate suppresses indomethacin-induced elevation of proinflammatory cytokines and gastric injury in rats.

  World journal of gastroenterology 20080814

• Irsogladine maleate counters the interleukin-1 beta-induced suppression in gap-junctional intercellular communication but does not affect the interleukin-1 beta-induced zonula occludens protein-1 levels in human gingival epithelial cells.

  Journal of periodontal research 20080201

• Irsogladine maleate potentiates the effects of nitric oxide on activation of cAMP signalling pathways and suppression of mesangial cell mitogenesis.

  British journal of pharmacology 20070601

• Anti-inflammatory agents in the management of alimentary mucositis.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20060601

• Regulation of IL-8 by Irsogladine maleate is involved in abolishment of Actinobacillus actinomycetemcomitans-induced reduction of gap-junctional intercellular communication.

  Cytokine 20060601

• Effects of irsogladine on P450-isoform specific activities in human hepatic microsomes.

  Arzneimittel-Forschung 20060101

• Irsogladine maleate influences the response of gap junctional intercellular communication and IL-8 of human gingival epithelial cells following periodontopathogenic bacterial challenge.

  Biochemical and biophysical research communications 20050729

• Irsogladine, an anti-ulcer drug, suppresses superoxide production by inhibiting phosphodiesterase type 4 in human neutrophils.

  Life sciences 20041119

• Phosphodiesterase inhibition by a gastroprotective agent irsogladine: preferential blockade of cAMP hydrolysis.

  Life sciences 20040827

• Phosphodiesterase type IV inhibitors prevent ischemia-reperfusion-induced gastric injury in rats.

  Journal of pharmacological sciences 20040701

• Irsogladine prevents monochloramine-induced gastric mucosal lesions by improving the decrease in mucosal blood flow due to the disturbance of nitric oxide synthesis in rats.

  Journal of pharmacological sciences 20031101

• Therapeutic benefits of irsogladine maleate on aphthous stomatitis induced by methotrexate in rheumatoid arthritis.

  The Journal of rheumatology 20030901

• [A case of idiopathic relapsing aphthous stomatitis which was effectively treated by irsogladine maleate].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20011201

• Suppressive effect of irsogladine maleate on N-methyl-N-nitro-N-nitrosoguanidine (MNNG)-initiated and glyoxal-promoted gastric carcinogenesis in rats.

  Toxicology 20010914